Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

COX-2 inhibitors from Chugai

Oct. 17, 1997

New antiarthritic agents described by Procter & Gamble

Oct. 15, 1997

Verigen licenses Italian rights to anti-TNF-alpha product

Oct. 14, 1997

Eltenac efficacy demonstrated in osteoarthritis

Oct. 13, 1997

FDA grant awarded for research on Dupuytren's disease therapy

Oct. 8, 1997

Clinical pharmacokinetic profile of rhIL-10

Oct. 8, 1997

Celgene initiates clinical trials for novel TNF-alpha inhibitors

Oct. 6, 1997

BB-2983 development discontinued

Oct. 6, 1997

Wyeth-Ayerst to promote Immunex's ENBREL in U.S.

Oct. 3, 1997

Genelabs Technologies reports phase III results from SLE trial

Oct. 3, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...